Drug
Omega-3 carboxylic acid clinical trials
Also written Epanova.
- studies test it
- 12
- open now
- 0
- in phase 3
- 5
- first study started
- 2002
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 3
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses omega-3 carboxylic acid is read from its arms, and is right about nine times in ten.
Testing it · 12
- Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With HypertriglyceridemiaCompletedPhase 3AstraZenecaNCT02104817Written as Epanova® (omega-3 carboxylic acids)
- Epanova® for Lowering Very High Triglycerides II (EVOLVE II)CompletedPhase 3AstraZenecaNCT02009865Written as Epanova
- A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.CompletedPhase 2AstraZenecaNCT02354976Written as Omega-3 carboxylic acid
- A Ph 1 Study of Epanova® in Healthy ChinesesCompletedPhase 1AstraZenecaNCT03574142Written as Epanova
- Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed ConditionsCompletedPhase 1AstraZenecaNCT02359045Written as Epanova®
- A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic PatientsCompletedPhase 2AstraZenecaNCT02279407Written as Omega-3 carboxylic acids
- A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEICompletedPhase 2AstraZenecaNCT02370537Written as Epanova® (omega-3 carboxylic acids)
- Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)CompletedPhase 1AstraZenecaNCT02859129Written as Epanova™ QD (2 x 1 g capsules)
- An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of PancreatitisCompletedPhase 1AstraZenecaNCT02189252Written as Epanova
- [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROLCompletedPhase 3AstraZenecaNCT01408303Written as omega-3-carboxylic acids, 2g
- EPANOVA in Crohn's Disease, Study 1CompletedPhase 3Tillotts Pharma AGNCT00613197Written as Epanova
- An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's DiseaseCompletedPhase 3Tillotts Pharma AGNCT00074542Written as Epanova™ (Omega-3 Free Fatty Acids)
As the comparator · 1 — what is tested is compared with omega-3 carboxylic acid
Codes
What other systems call omega-3 carboxylic acid · ClinicalTrials.gg INT001349
- UNII (FDA) F85N2YHE4EOMEGA-3-CARBOXYLIC ACIDSOne source FDA
- RxNorm 1652071One source FDA
- NCI Thesaurus C170252Omega-3-carboxylic AcidsOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | F85N2YHE4E | OMEGA-3-CARBOXYLIC ACIDS | One source FDA |
| RxNorm | 1652071 | — | One source FDA |
| NCI Thesaurus | C170252 | Omega-3-carboxylic Acids | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.